Siavosh Mahboobi

HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer

Nataša Stojanović, Zonera Hassan, Matthias Wirth et al. · Oncogene · 2016 · 104 citations

Oncology, Pancreatic Cancer, Medicine +8

Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy

Thomas Beckers, Siavosh Mahboobi · Drugs of the Future · 2003 · 101 citations

Pharmacotherapy, Pharmaceutical Chemistry, Tumor Biology +17

Synthetic 2-Aroylindole Derivatives as a New Class of Potent Tubulin-Inhibitory, Antimitotic Agents

Siavosh Mahboobi, Herwig Pongratz, Harald Hufsky et al. · Journal of Medicinal Chemistry · 2001 · 101 citations · Full text

Pharmaceutical Science, Chemoprevention Strategy, Cell Cycle +17

Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity

Siavosh Mahboobi, Andreas Sellmer, Mathias Winkler et al. · Journal of Medicinal Chemistry · 2010 · 96 citations · Full text

Histone Modifications, Chromatin, Medicine +13

Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases

Siavosh Mahboobi, Stefan Dove, Andreas Sellmer et al. · Journal of Medicinal Chemistry · 2009 · 90 citations · Full text

Histone Deacetylases, Hdac Inhibitors, Tumor Biology +17